EP1500652A4 — Quinazoline derivative and medicine
Assigned to Nippon Shinyaku Co Ltd · Expires 2006-05-03 · 20y expired
What this patent protects
An excellent antipruritic drug which functions by a new mechanism. Also provided is a quinazoline derivative represented by the following general formula (1) or a salt thereof: (1) wherein R1 represents hydrogen or alkyl; ring Q represents cyclohexylene or phenylene; A1 and A2 ea…
USPTO Abstract
An excellent antipruritic drug which functions by a new mechanism. Also provided is a quinazoline derivative represented by the following general formula (1) or a salt thereof: (1) wherein R1 represents hydrogen or alkyl; ring Q represents cyclohexylene or phenylene; A1 and A2 each represents a single bond or alkylene; E represents -NHCO-, etc.; A3 represents a single bond, a divalent (un)saturated aliphatic hydrocarbon group, etc.; R3 represents a noncyclic aliphatic hydrocarbon group, etc.; and R4 and R5 are the same or different and each represents hydrogen, alkyl, etc. The antipruritic drug contains as an active ingredient the derivative or a pharmaceutically acceptable salt of the derivative.
Drugs covered by this patent
- Kalydeco (IVACAFTOR) · Vertex Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.